daytrades march 19 afternoon, page-140

CXS Could be one to look out for come monday.

The Company has a meeting with the ODAC, which will make a recommendation to FDA. We should hear the outcome monday afternoon or tuesday morning.

Extracts from a recent Wilson HTM report:
"Our view is that ODAC will recommend Omapro. Although valid issues were raised on efficacy and trial conduct, ODAC did not contest Omapros benefit:risk ratio and the panel will be mindful that there is no alternative, approved therapy for the patients they are discussing".

"but if ODAC vote is affirmative then the price should be 80-90 cps"

"We revise our target to $1.70"

Current share price $.70